Canine Atopic Dermatitis Treatment Market Outlook (2024 to 2034)

The canine atopic dermatitis treatment market size expects a considerable valuation bump, from US$ 1,182.60 million in 2024 to US$ 1,620.50 million in 2034. The updated report points to a CAGR of 3.20% CAGR from 2024 to 2034. That is a significant dip from the previous CAGR of 7.60% observed between 2019 and 2023.

Attributes Details
Canine Atopic Dermatitis Treatment Market Size, 2023 US$ 1,192.20 million
Canine Atopic Dermatitis Treatment Market Size, 2024 US$ 1,182.60 million
Canine Atopic Dermatitis Treatment Market Size, 2034 US$ 1,620.50 million
Value CAGR (2024 to 2034) 3.20%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Market Highlights

Fundings for Developing Regenerative Medicines Rise in the Market

New treatments are being developed to help canines with itchy skin. These treatments comprise stem cell therapy and Platelet-rich Plasma (PRP) injections. Some other effective products for treating CAD are Cytopoint (lokivetmab), cASCs or cASC-EVs, and Oclacitinib Maleate (Apoquel, Zoetis). These dog allergy treatments use the body’s natural healing powers to repair the skin.

They also reduce swelling and make the immune system stronger. They calm down the immune system and use special cells to fix skin damage. These treatments can help canines in the long run. As such, more research is being conducted on the potential of regenerative medicines. Investments are flooding in the veterinary dermatology market to develop these treatment approaches more effectively.

For example, Gallant Therapeutics raised over US$ 15 million in Series A Funding in January 2024. The top investors were BOLD Capital, Digitalis Ventures, and Hill Creek Partners. The funding has accelerated the company’s pipeline development of allogeneic stem cell therapeutics.

Global Rise in Pet Ownership Fosters Market Growth

More people around the world are getting pets. This is especially true in places where the economy is growing. This means that there are more canines needing treatment for skin problems like canine atopic dermatitis.

In countries where more people are becoming wealthier, there’s a higher need for vets and treatment for pets. Pet humanization trends also contribute to this. Rise in middle-class populations and shifting societal attitudes toward pets aid market growth.

It is estimated that 33% of households have a pet. There are nearly 471 million pet dogs and 370 million pet cats globally. Dogs make up for the top category of insured pets.

Canine Atopic Dermatitis Treatment Market Trends Analysis

  • Personalized medicine is being favored as molecular diagnostics ate genetics are advancing. This is causing a demand for specialized treatments.
  • Telemedicine and remote consultations are helping the market to develop. Convenience factors play an important role in this.
  • The awareness of what triggers canine allergic skin disease is rising. This is causing a demand for products and services that address the allergens found in the home environment.
  • Artificial intelligence and big data analytics are making their way in this market. They are helping in treatment optimization and predictive modeling for cAD treatment. The aim is to optimize treatment procedures.
  • Technological developments in diagnostic techniques are flourishing in the market. Allergy testing and treatment modalities are improving with technical advancements.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Canine Atopic Dermatitis Treatment Market Opportunity Analysis

  • New biomarkers, like certain microbiota can help in the evaluation of the cAD predisposition. Companies can develop microbiota-based therapies to restore the balance in the skin microbiome.
  • Providing home-based cAD treatment solutions can be opportunistic. Making them convenient to use and cost-effective can enhance prospects for growth.
  • Companies can hop on the snowballing demand for functional foods and nutraceuticals for pet health. Pet food formulations that support skin health and immunity can be lucrative.
  • Businesses can provide natural and holistic treatments for canine atopic dermatitis. Non-pharmaceutical options can appeal to pet owners who want gentle and natural options to manage their pet’s health.
  • Targeted therapies can be provided in this market. This can include targeting key pathways in barriers to dysfunction, inflammation, and immunity dysregulation. With fewer side effects, the adoption of targeted therapies can significantly rise.

Comparative View of Market Adjacent to Canine Atopic Dermatitis Treatment

This part compares the Canine Flu Therapeutics Market and the Canine Arthritis Treatment Market.

Canine Atopic Dermatitis Treatment Market:

Attributes Canine Atopic Dermatitis Treatment Market
CAGR (2024 to 2034) 3.20%
Growth Factors
  • Increasing prevalence globally.
  • Advancements in treatment options.
Future Opportunities Growth in pet ownership.
Market Trends Increasing pet humanization trends.

Canine Flu Therapeutics Market:

Attributes Canine Flu Therapeutics Market
CAGR (2024 to 2034) 4.1%
Growth Factors
  • Increasing government support.
  • Rising research and development activities by manufacturers.
Future Opportunities Rise in infection rates.
Market Trends Increasing consumer expenditure on veterinarian services.

Canine Arthritis Treatment Market:

Attributes Canine Arthritis Treatment Market
CAGR (2024 to 2034) 4.20%
Growth Factors
  • Increasing awareness for managing pet’s arthritis.
  • Advancements in veterinary pharmaceuticals.
Future Opportunities Expansion of veterinary services.
Market Trends Growing demand for minimally invasive surgical procedures.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Immunosuppressants Gain Top Market Shares as the Leading Drug Class

Segment Immunosuppressants (Drug Class)
Value Share (2024) 42.10%

The immunosuppressants segment garnered top canine atopic dermatitis treatment market shares in 2024. The cases and severity of atopic dermatitis in canines are rising. As such, effective treatment solutions like immunosuppressants are being demanded. Immunosuppressants like calcineurin inhibitors and corticosteroids can effectually control the symptoms of this disease.

There are cases where secondary bacterial infections happen. In these types of cases, immunosuppressants are used as an aide for antibiotic therapy. The market shares of this segment are high because they can be used in comprehensive treatment plans for the long-term management of CAD.

Oral Route of Administration is Highly Preferred in the Market

Segment Oral (Route of Administration)
Value Share (2024) 46.70%

The oral route of administration segment holds the top canine atopic dermatitis treatment market shares in 2024. Oral medications are popular for cAD treatment. They’re easy to administer and work throughout the whole body. They are especially useful for giving relief beyond just the surface. Vets can adjust doses on how bad the symptoms are and how the canine responds.

Oral meds last longer than creams. This makes it easier for pet owners to manage the disease. They also reduce the need for strong steroids that can have side effects. New oral cAD treatment medications are hitting the market. They come with better tastes and are easier to swallow. This makes it preferrable in the market among pet owners and vets.

Country-wise Insights

Countries Value CAGR (2024 to 2034)
United States 1.90%
Germany 2.70%
Malaysia 3.90%
Thailand 4.20%
India 5.30%

Pets are being Insured More and Raising the Demand in the United States

The demand for canine atopic dermatitis treatment in the United States to rise at a 1.90% CAGR till 2034. More pet owners are getting insurance for their pet animals. During the end of 2022, it was noticed that nearly 4.8 million pets were insured in the United States. Pet owners tend to pay more for specialized care as they get concerned about the health of their animals. So, companies can make specialized or personalized medicines for canine skin allergies.

There are also the FDA’s Center for Veterinary Medicine (CVM) Innovation Initiatives and the Minor Use and Minor Species (MUMS) designation. The presence of these programs makes it easier to get drug approvals and bring them to the market.

Zoetis Inc. and Elanco Animal Health are valuable in the United States. They are among the top players in the United States market. These companies invest in R&D heavily to launch new dermatology products for canines.

High Allergy Rates Augment Sales in Germany

The sales of canine atopic dermatitis treatment in Germany will increase at a 2.70% CAGR until 2034. Allergies, like atopic dermatitis, are common here due to pollen and dust, so there's a big need for dog skin allergy treatments. This is leading to more research and new medicines.

In Germany, people adore their pets and spend a lots on their health, especially for skin issues like atopic dermatitis in canines. Germany has many vet clinics and experts in pet skin problems, which helps in finding better treatments. Some German pet owners are also showing a preference for natural remedies, like herbs or homeopathy. This is creating a small market niche for these treatments.

Bayer AG and Virbac GmbH are prominent in Germany. They are famous for their product innovations and consumer-centric approaches. They provide comprehensive support to vets and pet owners.

Spike in Pet Ownership Aids Market Growth in Malaysia

The canine atopic dermatitis treatment market growth in Malaysia is estimated at a 3.90% CAGR through 2034. Atopic dermatitis in canines is common due to Malaysia’s warm and humid climate. Nearly 51.1% of the country’s population has a pet. Cats are more adopted than cats here.

Nearly 77.7% of pet owners have at least one cat and 14.9% of pet owners have dogs. The pet humanization trend is picking up heat here. Also, the middle-class population is growing in Malaysia. These factors are letting people invest in veterinary dermatology and aiding market development.

Biovet Sdn Bhd and Merial Malaysia Sdn Bhd are eminent in Malaysia. These businesses focus on marketing efforts to reach a wider audience. They also ally with local partners to widen their networks.

Pet Humanization Trends are Visibly Catapulting Demand in Thailand

Canine atopic dermatitis treatment demand in Thailand shall amplify at a 4.20% CAGR till 2034. The pet healthcare industry in Thailand is maturing. Urbanization in the country is leading to a spike in pet ownership. Thai people treat their pets like family and want good healthcare for them. Pet humanization trends are going to intensify and aid in market growth in Thailand.

Merck Animal Health and Ceva Animal Health (Thailand) Co. Ltd. are headquartered here. These businesses focus on alliances with local distributors. They also provide training and support to vets.

Veterinary Tourism is Creates a Surge in Sales in India

Canine atopic dermatitis treatment sales in India can increase at a 5.30% CAGR till 2034. People from countries like Bangladesh, Nepal, and Sri Lanka visit India for cheaper vet care.

Affordable care is important in India due to the price-sensitive populace. India’s pet population is also growing. Dog lovers account for nearly 68% of the population, while cats belong to nearly 20% of Indian pet owners. As more people are getting pets, the demand for canine atopic dermatitis treatment is bound to increase in India.

Indian Immunologists Limited (IIL) and Intas Pharmaceuticals Ltd. are located here. These businesses are increasing their offering portfolios to launch innovative solutions. They also want them to be cost-effective, so research is an all-time necessity for these businesses.

Competitive Landscape

The canine atopic dermatitis treatment market is highly competitive. The arena is ruled by leading companies including Zoetis Inc., Elanco Animal Health, and Bayer Animal Health. To sustain their supremacy, these corporations rely on broad product portfolios and reach.

Other important rivals include Virbac, Ceva Animal Health, and Vetoquinol. Also, businesses like Dechra Pharmaceuticals, Boehringer Ingelheim Animal Health, and Merial (now a part of Boehringer Ingelheim) are improving their presence in the market through collaborations and acquisitions. Regulatory compliance, pricing diplomacies, and technical improvements make up for the competitiveness of this market.

Recent Developments

  • In June 2023, the FDA approved Apoquel Chewable (Oclacitinib chewable) tablets produced by Zoetis. The medication is developed to control pruritus related to allergic dermatitis and atopic dermatitis among dogs aged 1 year or older.
  • In January 2023, Royal Canin North America launched Skintopic. It was launched to manage canine atopic dermatitis.

Key Players in the Market

  • Zoetis Inc.
  • Elanco Animal Health
  • Bayer Animal Health
  • Boehringer Ingelheim
  • Virbac
  • Vetoquinol
  • Ceva Animal Health
  • Dechra Pharmaceuticals
  • Merial (now part of Boehringer Ingelheim)
  • Merck Animal Health

Key Coverage in the Canine Atopic Dermatitis Treatment Market Report

  • Adjacent Study on the Canine Atopic Dermatitis Market, Canine Atopic Dermatitis Treatment Drugs Market, and the Veterinary Dermatology Drugs Market
  • Demand Analysis of Europe Canine Atopic Dermatitis Treatment Market
  • Global Trends in Canine Atopic Dermatitis Market
  • Consumption Analysis of Medications for Canine Atopic Dermatitis Market

Canine Atopic Dermatitis Treatment Market Segmentation

By Drug Class:

  • Corticosteroids
  • Immunosuppressants
  • Antibiotics
  • Antihistamines
  • Emollients
  • Essential Fatty Acids
  • Antipruritic
  • Monoclonal Antibodies

By Route of Administration:

  • Topical
  • Oral
  • Injectable

By Distribution Channel:

  • Veterinary Hospitals
  • Veterinary Clinics
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific (APAC)
  • Middle East & Africa (MEA)
  • Japan

Frequently Asked Questions

What is the Worth of the Canine Atopic Dermatitis Treatment Market?

The canine atopic dermatitis treatment industry is valued at US$ 1,82.60 million in 2024.

What is the Probable CAGR of the Canine Atopic Dermatitis Treatment Industry?

The market is estimated to increase at a 3.20% CAGR through 2034.

What is the Future Stance for the Canine Atopic Dermatitis Treatment Industry?

The market is expected to be worth US$ 1,620.50 million by 2034.

Which is the Preferred Drug Class in the Canine Atopic Dermatitis Treatment Industry?

Immunosuppressants are highly preferred in the market.

Which Country is Rising at a Higher CAGR in the Canine Atopic Dermatitis Treatment Industry?

The market in India is predicted to expand at a 5.30% CAGR through 2034.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Manufacturer

            3.5.1.2. Mid-Level Participants (Traders)

            3.5.1.3. Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Distributors

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ Billion) & Volume (Units) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Drug Class, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Drug Class, 2024 to 2034

        5.3.1. Corticosteroids

        5.3.2. Immunosuppressant

        5.3.3. Antibiotics

        5.3.4. Antihistamines

        5.3.5. Emollients

        5.3.6. Essential Fatty Acids

        5.3.7. Antipruritic

        5.3.8. Monoclonal Antibodies

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Route of Administration, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Route of Administration, 2024 to 2034

        6.3.1. Topical

        6.3.2. Oral

        6.3.3. Injectable

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Distribution Channel, 2019 to 2023

    7.3. Current and Future Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Distribution Channel, 2024 to 2034

        7.3.1. Veterinary Hospitals

        7.3.2. Veterinary Clinics

        7.3.3. Retail Pharmacies

        7.3.4. Drug Stores

        7.3.5. Mail Order Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Billion) & Volume (Units) Analysis By Region, 2019 to 2023

    8.3. Current Market Size Value (US$ Billion) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Class

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    15.1. Historical Market Size Value (US$ Billion) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    15.2. Market Size Value (US$ Billion) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Class

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2023

            16.1.2.1. By Drug Class

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2023

            16.2.2.1. By Drug Class

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2023

            16.3.2.1. By Drug Class

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2023

            16.4.2.1. By Drug Class

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2023

            16.5.2.1. By Drug Class

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2023

            16.6.2.1. By Drug Class

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2023

            16.7.2.1. By Drug Class

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2023

            16.8.2.1. By Drug Class

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2023

            16.9.2.1. By Drug Class

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2023

            16.10.2.1. By Drug Class

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2023

            16.11.2.1. By Drug Class

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2023

            16.12.2.1. By Drug Class

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2023

            16.13.2.1. By Drug Class

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2023

            16.14.2.1. By Drug Class

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2023

            16.15.2.1. By Drug Class

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2023

            16.16.2.1. By Drug Class

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2023

            16.17.2.1. By Drug Class

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2023

            16.18.2.1. By Drug Class

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2023

            16.19.2.1. By Drug Class

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2023

            16.20.2.1. By Drug Class

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2023

            16.21.2.1. By Drug Class

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2023

            16.22.2.1. By Drug Class

            16.22.2.2. By Route of Administration

            16.22.2.3. By Distribution Channel

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2023

            16.23.2.1. By Drug Class

            16.23.2.2. By Route of Administration

            16.23.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Zoetis Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

                18.1.1.5.2. Product Strategy

                18.1.1.5.3. Channel Strategy

        18.1.2. Elanco Animal Health Incorporated

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

                18.1.2.5.2. Product Strategy

                18.1.2.5.3. Channel Strategy

        18.1.3. Virbac

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

                18.1.3.5.2. Product Strategy

                18.1.3.5.3. Channel Strategy

        18.1.4. Elanco Animal Health

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

                18.1.4.5.2. Product Strategy

                18.1.4.5.3. Channel Strategy

        18.1.5. Merck KGaA

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

                18.1.5.5.2. Product Strategy

                18.1.5.5.3. Channel Strategy

        18.1.6. Johnson & Johnson Services, Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

                18.1.6.5.2. Product Strategy

                18.1.6.5.3. Channel Strategy

        18.1.7. Kindred Biosciences, Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

                18.1.7.5.2. Product Strategy

                18.1.7.5.3. Channel Strategy

        18.1.8. Nippon Zenyaku Kogyo Co., Ltd.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

                18.1.8.5.2. Product Strategy

                18.1.8.5.3. Channel Strategy

        18.1.9. Bioiberica S.A.U

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

                18.1.9.5.2. Product Strategy

                18.1.9.5.3. Channel Strategy

        18.1.10. Dechra Pharmaceuticals PLC

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

                18.1.10.5.2. Product Strategy

                18.1.10.5.3. Channel Strategy

        18.1.11. Toray Industries, Inc.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

                18.1.11.5.2. Product Strategy

                18.1.11.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Canine Arthritis Treatment Market

October 2019

REP-GB-3552

February 2024

333 pages

Healthcare

Canine Dilated Cardiomyopathy Drugs Market

July 2019

REP-GB-10023

July 2023

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Canine Atopic Dermatitis Treatment Market